GNA13
Overview
GNA13 encodes a Gα13 heterotrimeric G-protein subunit and is a recurrently inactivated tumor suppressor in germinal-center-derived B-cell lymphomas.
Alterations observed in the corpus
- Mutated in 26% of classic Hodgkin lymphoma (cHL) cases in a combined WGS+WES cohort (n=61) PMID:36723991.
- Enriched in EBV-negative cHL cases PMID:36723991.
- Timed as an early event preceding large chromosomal gains/WGD in cHL evolution PMID:36723991.
- GNA13 was recurrently mutated in DLBCL and FL through whole-genome/exome sequencing, implicating G-protein signaling in lymphomagenesis PMID:21796119
- GNA13 is recurrently mutated in DLBCL by whole-exome sequencing of 55 tumors (MutSig analysis, Broad Institute) PMID:22343534
- Mutations in 20% of PCNSL; recurrent homozygous deletion PMID:25991819
- Preferentially mutated in GCB-DLBCL alongside SOCS1, STAT6, and TNFRSF14; GNA13 mutations are a GCB-enriched driver event in the comprehensive 1,001-patient DLBCL analysis PMID:28985567
Cancer types (linked)
- CHL — common, early driver mutation in HRS cells PMID:36723991.
Co-occurrence and mutual exclusivity
- Grouped among early drivers (B2M, BCL7A, GNA13, PTPN1) preceding WGD PMID:36723991.
Therapeutic relevance
- Not directly evaluated in the corpus.
Open questions
- How temporally early cHL drivers (B2M, BCL7A, GNA13, PTPN1) relate to the equivalent early events in DLBCL and other AID-exposed B-cell lymphomas PMID:36723991.
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:28985567
This page was processed by wiki-cli on 2026-05-15.